Vericel Corporation (VCEL)

NASDAQ: VCEL · IEX Real-Time Price · USD
23.20
-0.55 (-2.32%)
Sep 30, 2022 4:00 PM EDT - Market closed
-2.32%
Market Cap 1.09B
Revenue (ttm) 155.22M
Net Income (ttm) -16.45M
Shares Out 47.18M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE 185.19
Dividend n/a
Ex-Dividend Date n/a
Volume 395,796
Open 23.79
Previous Close 23.75
Day's Range 23.12 - 24.64
52-Week Range 22.06 - 52.87
Beta 2.06
Analysts Buy
Price Target 46.51 (+100.5%)
Earnings Date Nov 7, 2022

About VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric pa... [Read more...]

Industry Biotechnology
IPO Date Feb 4, 1997
CEO Dominick Colangelo
Employees 281
Stock Exchange NASDAQ
Ticker Symbol VCEL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for VCEL stock is "Buy." The 12-month stock price forecast is 46.51, which is an increase of 100.47% from the latest price.

Price Target
$46.51
(100.47% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Vericel to Present at the Ladenburg Thalmann Healthcare Conference

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief Fi...

1 week ago - GlobeNewsWire

Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company ...

3 weeks ago - GlobeNewsWire

How Much Upside is Left in Vericel Corporation (VCEL)? Wall Street Analysts Think 53%

The average of price targets set by Wall Street analysts indicates a potential upside of 52.8% in Vericel Corporation (VCEL). While the effectiveness of this highly sought-after metric is questionable, ...

1 month ago - Zacks Investment Research

Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -46.15% and 3.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Vericel Reports Second Quarter 2022 Financial Results

Second Quarter Total Net Revenue of $37.0 Million

1 month ago - GlobeNewsWire

Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of ...

CAMBRIDGE, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the publicatio...

2 months ago - GlobeNewsWire

Vericel to Report Second-Quarter 2022 Financial Results on August 3, 2022

CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will r...

2 months ago - GlobeNewsWire

Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 0% and 6.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Vericel Reports First Quarter 2022 Financial Results

First Quarter Total Net Revenue of $36.1 Million

4 months ago - GlobeNewsWire

Vericel to Report First-Quarter 2022 Financial Results on May 4, 2022

CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following...

5 months ago - GlobeNewsWire

Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022

CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Col...

6 months ago - GlobeNewsWire

Vericel to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022

CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Col...

7 months ago - GlobeNewsWire

Vericel Announces Appointment of Jonathan Siegal as Principal Accounting Officer

CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Board...

7 months ago - GlobeNewsWire

Vericel Corporation (VCEL) Q4 Earnings Miss Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -47.06% and 0.24%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Earnings Preview: Vericel Corporation (VCEL) Q4 Earnings Expected to Decline

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Vericel to Report Fourth-Quarter 2021 Financial Results on February 24, 2022

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following ...

7 months ago - GlobeNewsWire

Vericel Announces Plans for a New State-of-the-Art Cell Therapy Manufacturing Facility to Support Long-Term Growth

CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it has en...

7 months ago - GlobeNewsWire

Vericel to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

8 months ago - GlobeNewsWire

Vericel to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on Nov...

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

10 months ago - GlobeNewsWire

Vericel Corporation (VCEL) Reports Q3 Loss, Misses Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -266.67% and -11.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Recap: Vericel Q3 Earnings

Vericel (NASDAQ:VCEL) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

10 months ago - Benzinga

Vericel Reports Third Quarter 2021 Financial Results

Third Quarter Total Net Revenue of $34.5 Million

10 months ago - GlobeNewsWire

Earnings Preview: Vericel Corporation (VCEL) Q3 Earnings Expected to Decline

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

Vericel to Report Third-Quarter 2021 Financial Results on November 9, 2021

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following ...

11 months ago - GlobeNewsWire